JESSICA HOBAN: Open Payments
NPI 1710369392 · BEL AIR, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$599 in 17 payments from 10 companies in 2025. Trend: 2023 $704 · 2024 $172 · 2025 $599
Food & beverage: $500Education: $99
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $134 |
| Janssen Biotech, Inc. | 1 | $99 |
| Daiichi Sankyo Inc. | 3 | $88 |
| TerSera Therapeutics LLC | 3 | $77 |
| Merck Sharp & Dohme LLC | 2 | $45 |
| Caris MPI, Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $36 |
| Exelixis Inc. | 1 | $32 |
| PFIZER INC. | 1 | $25 |
| Syndax Pharmaceuticals, Inc. | 1 | $25 |
Products named: CALQUENCE, RYBREVANT, Enhertu, KEYTRUDA, Zoladex, MI CANCER SEEK, Xermelo, FRUZAQLA.
Industry payments across MD — which companies pay providers there.
